In the last trading session, 1.21 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.44. With the company’s per share price at $0.26 changed hands at $0.0 or -0.66% during last session, the market valuation stood at $65.62M. ADAP’s last price was a discount, traded about -469.23% off its 52-week high of $1.48. The share price had its 52-week low at $0.20, which suggests the last value was 23.08% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 10-day average is 3.38 million shares, with the 3-month average coming to 1.72 million.
Analysts gave the Adaptimmune Therapeutics Plc ADR (ADAP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 1 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ADAP as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Adaptimmune Therapeutics Plc ADR’s EPS for the current quarter is expected to be -0.17.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP was in red as seen at the end of in last trading. With action 30.15%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -52.40%, with the 5-day performance at 30.15% in the green. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -46.58% down. Looking at the short shares, we see there were 5.64 million shares sold at short interest cover period of 4.59 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 91.33% from its current market value. According to analyst projections, ADAP’s forecast low is 1 with 4 as the target high. To hit the forecast high, the stock’s price needs a -1438.46% plunge from its current level, while the stock would need to soar -284.62% for it to hit the projected low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Year-over-year growth is forecast to reach -76.38% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 6.97M. 7 analysts are of the opinion that Adaptimmune Therapeutics Plc ADR’s revenue for the current quarter will be 9.62M. The company’s revenue for the corresponding quarters a year ago was 5.68M and 128.23M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 22.80%. The estimates for the next quarter sales put growth at -92.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 26.53%. The 2025 estimates are for Adaptimmune Therapeutics Plc ADR earnings to decrease by -62.07%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report on 2025-Mar-23.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.31% of Adaptimmune Therapeutics Plc ADR shares while 49.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 49.74%. There are 49.59% institutions holding the Adaptimmune Therapeutics Plc ADR stock share, with MATRIX CAPITAL MANAGEMENT COMPANY, LP the top institutional holder. As of 2024-06-30, the company held 2.5415% of the shares, roughly 38.97 million ADAP shares worth $38.0 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 1.787% or 27.4 million shares worth $26.72 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were SPDR INDEX SHARES FUNDS-SPDR(R) Portfolio Developed World ex-US ETF and SEI INSTITUTIONAL INTERNATIONAL TRUST-SIT INTERNATIONAL EQUITY FUND . With 272.49 shares estimated at $69867.0 under it, the former controlled 0.11% of total outstanding shares. On the other hand, SEI INSTITUTIONAL INTERNATIONAL TRUST-SIT INTERNATIONAL EQUITY FUND held about 0.10% of the shares, roughly 246.74 shares worth around $63265.0.
